Clarity Completes Site Activation for SARTATE™ Clinical Trial for the Treatment of Meningioma
Sydney, Australia 10 July 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at Royal North Shore Hospital in Sydney has been completed and recruitment has commenced for its SARTATE™ clinical trial. Clarity’s SARTATE™ trial is a Peptide Receptor Radionuclide Therapy clinical trial…